Improving bone health and reducing tumor growth in multiple myeloma patients
Manipulating the N-end Rule Protein Degradation Pathway to Build Bone and Decrease Tumor Growth in Multiple Myeloma Bone Disease
This study is exploring a new way to help people with multiple myeloma-related bone disease by using a special molecule that targets a protein important for bone health, with the hope of reducing bone pain and the risk of fractures while improving cancer treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10813176 on NIH RePORTER |
What this research studies
This research investigates a new approach to treat bone disease associated with multiple myeloma by targeting a specific protein pathway. The study focuses on a small molecule called XRK that interacts with the p62 protein, which plays a crucial role in bone formation and cancer cell survival. By manipulating this pathway, the research aims to promote new bone growth and enhance the effectiveness of existing cancer treatments. Patients may benefit from this innovative strategy that seeks to alleviate bone pain and reduce fracture risk.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple myeloma who are experiencing bone disease and related complications.
Not a fit: Patients without multiple myeloma or those who do not have bone disease may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve bone health and reduce tumor growth in patients with multiple myeloma.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting the p62 protein in cancer treatment, indicating potential for success in this study.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Chirgwin, John M — Indiana University Indianapolis
- Study coordinator: Chirgwin, John M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.